More lawsuits alleging securities fraud were brought against life sciences companies in 2019 than the year before, a new report from law firm Dechert LLP finds. And the near 13% year-over-year increase continues a trend that has seen the number of such suits more than double since 2014.
Report: Securities Lawsuits Against Life Sciences Firms Still On The Rise
More investor suits were brought against life sciences companies in 2019 than in any of the past five years, according to a new report from law firm Dechert LLP. The increase continues a trend that has seen the number of such suits more than double since 2014.
More from Legal & IP
• By
US President Trump has imposed sweeping tariffs that encompass medtech. These are expected to drive up costs, disrupt supply chains and hinder innovation, likely driving the EU to seek new trade partnerships to mitigate the impact.
• By
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.